Aardvark Therapeutics Plunges 25.25% Amid Market Volatility

Aardvark Therapeutics' stock price plummeted by 25.25% in pre-market trading on April 7, 2025, sparking concerns among investors about the company's future prospects.

Cantor Fitzgerald reaffirmed its "Overweight" rating for Aardvark Therapeutics, setting an "outperform" rating and a $21.00 target price for the company. This move by Cantor Fitzgerald suggests that despite the recent drop in stock price, the firm remains optimistic about Aardvark's long-term growth potential.

Investors are closely monitoring Aardvark's performance, as the significant drop in stock price could be attributed to various factors, including market volatility, regulatory changes, or internal company issues. The reaffirmation of the "Overweight" rating by Cantor Fitzgerald provides some reassurance to investors, indicating that the firm believes in Aardvark's ability to overcome current challenges and achieve its growth targets.